'Challenged road ahead as Novo attempts to return to its former glory': Seigerman

Key Concepts

• GLP-1s: Glucagon-like peptide-1 receptor agonists – a class of drugs initially developed for type 2 diabetes, now widely used for weight loss.
• Wegovy & Zepbound: Specific GLP-1 medications – Wegovy (Novo Nordisk) is an injectable, now available in pill form; Zepbound (Eli Lilly) is an injectable competitor.
• Oral GLP-1: The newly approved pill form of Wegovy, offering an alternative to injections.
• Priority Review Voucher: A mechanism used by the FDA to expedite the review of certain drugs.
• Counter-Detailing: A pharmaceutical marketing tactic where a company attempts to discredit a competitor’s product to healthcare providers.
• Cash Pay: Paying for medication directly, outside of insurance coverage.
• Telehealth Platforms: Virtual healthcare services, like Rowe Health, offering access to medications and medical consultations remotely.

Novo Nordisk’s Wegovy Pill Approval: A Detailed Analysis

Introduction of the Wegovy Pill & Comparison to Injections

The United States has approved the first-ever GLP-1 pill for obesity treatment, a development that significantly impacted Novo Nordisk’s stock price. The pill form of Wegovy offers comparable weight loss efficacy to the existing injectable version. However, it requires daily administration, which may appeal to those averse to needles but could be a drawback for others. This new format expands access to the drug, catering to patient preferences for either pill or injection delivery.

Pricing Considerations

While official pricing hasn’t been released, initial estimates suggest the oral GLP-1 will likely be slightly less expensive than the injectables, potentially starting around $150 per month and increasing with higher doses. It’s important to note that the price of injectables has been decreasing, with recent deals bringing access through Medicare to $254 per month. The actual price paid by patients will likely vary, with the list price representing a cash pay option. Expect prices to continue to fall, potentially reaching the $200 per month range later in the decade.

Novo Nordisk’s Strategic Need for a Win

Evan Zukerman, Managing Director, Head of Healthcare Research at BMO Capital Markets, emphasized the critical need for this approval for Novo Nordisk. 2025 had been a challenging year for the company, with concerns about execution and market share gains by Eli Lilly. The loss of a bidding war with Pfizer further underscored the need for a positive catalyst. This pill approval represents a significant win, though Zukerman cautions that much work remains. He stated, “They really needed this win to start off 2026…They’re not out of the woods yet. Plenty more to do, but this definitely helps.”

Competitive Landscape & Lilly’s Orforglipron

Eli Lilly is a key competitor, with its oral GLP-1, Orforglipron, expected to be approved in the first or second quarter of 2026. The potential use of a Priority Review Voucher by Lilly could accelerate this timeline. Novo Nordisk gains a temporary head start, but Zukerman stresses that this advantage won’t last indefinitely, anticipating aggressive marketing and launch strategies from Lilly. Historically, being first to market doesn’t guarantee dominance, as competitors can quickly establish themselves with differentiated products and counter-detailing efforts.

Market Share Dynamics & Patient Behavior

The question of whether first-to-market status guarantees a larger market share is complex. While initial momentum can be beneficial, a strong competitor entering the market shortly after can level the playing field. Patient inertia is also a factor; those already benefiting from Wegovy or Zepbound injections are likely to remain on those treatments due to established routines and minimal side effects. However, the pill format offers a compelling option for patients who have been hesitant to start GLP-1 therapy or are seeking a maintenance therapy alternative to weekly injections. Zukerman highlighted the ease of use of the injections, noting they use a “tiny needle.”

Pricing Trends & Insurance Coverage

The current list price of $1,100 per month for GLP-1s doesn’t reflect the actual price Novo Nordisk or Eli Lilly receives, or what patients pay. Zepbound starter doses are currently priced at $299. The evolution of insurance coverage is a key challenge. Employers are increasingly pushing patients towards cash pay options to manage budgetary constraints. Access is improving, particularly through telehealth platforms like Rowe Health, which bypass traditional barriers to obesity medicine.

Novo Nordisk’s Stock Rating & Future Outlook

Zukerman maintains a “Market Perform” (Hold) rating on Novo Nordisk’s stock. While the pill approval is positive, it’s not sufficient to warrant an upgrade. He requires evidence of a successful pill launch – including adequate supply, sustained growth in the GLP-1 market, and a clear strategic vision from the new CEO – to become more bullish. He expressed concerns about potential slowing volumes in injectables and further price erosion. He criticized a previous bidding war for Medicare as “reckless” and seeks “smart BD [business development] that helps propel the long term trajectory of the company.” He anticipates the pill launch could generate $1.6 billion in revenue next year, significantly exceeding previous consensus estimates of $600-700 million.

Accessibility & Prescription Requirements

These medications require a prescription and are intended for patients with obesity as a serious medical condition. Access has become easier, particularly through cash pay options and telehealth platforms. Zukerman emphasized the increasing availability of these medications through platforms like Rowe Health, which streamline the process of obtaining a prescription and medication.

Conclusion

The approval of the Wegovy pill represents a significant advancement in obesity treatment, offering a more accessible option for patients. While Novo Nordisk has secured a temporary lead in the oral GLP-1 market, competition from Eli Lilly’s Orforglipron is imminent. The success of the pill launch, coupled with strategic execution by Novo Nordisk, will be crucial in determining the company’s future trajectory. The evolving landscape of pricing, insurance coverage, and access through telehealth platforms will also play a vital role in shaping the market for these transformative medications.